上市后个例安全性报告(ICSRs)E2B(R3)实施指南问答文件(征求意见稿)

2019-08-01 国家药品监督管理局(NMPA) NMPA

上市后个例安全性报告(ICSRs)E2B(R3)实施指南问答文件(征求意见稿)

中文标题:

上市后个例安全性报告(ICSRs)E2B(R3)实施指南问答文件(征求意见稿)

发布日期:

2019-08-01

简要介绍:

上市后个例安全性报告(ICSRs)E2B(R3)实施指南问答文件(征求意见稿)

相关资料下载:
[AttachmentFileName(sort=1, fileName=1.pdf)] GetToolGuiderByIdResponse(projectId=1, id=7b4a21c0025e9a8c, title=上市后个例安全性报告(ICSRs)E2B(R3)实施指南问答文件(征求意见稿), enTitle=, guiderFrom=NMPA, authorId=0, author=, summary=上市后个例安全性报告(ICSRs)E2B(R3)实施指南问答文件(征求意见稿), cover=, journalId=0, articlesId=null, associationId=1683, associationName=国家药品监督管理局(NMPA), associationIntro=国家药品监督管理局(NMPA), copyright=0, guiderPublishedTime=Thu Aug 01 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<p>上市后个例安全性报告(ICSRs)E2B(R3)实施指南问答文件(征求意见稿)</p>, tagList=[TagDto(tagId=459161, tagName=个例安全性报告)], categoryList=[CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=政策, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=306, appHits=1, showAppHits=0, pcHits=61, showPcHits=305, likes=0, shares=0, comments=0, approvalStatus=1, publishedTime=Tue Aug 09 13:33:14 CST 2022, publishedTimeString=2019-08-01, pcVisible=1, appVisible=1, editorId=0, editor=小小医者, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=小小医者, createdTime=Wed Aug 10 04:33:44 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Tue Jan 02 13:49:35 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=1.pdf)])
1.pdf
下载请点击:
评论区 (0)
#插入话题